The prior authorization was denied. What’s more, in an unusual move, the insurer declined to allow a “peer-to-peer” review of ...

Read the Patient Information Leaflet and Instructions for Use if available from your pharmacist before you start using immune globulin and each time you get a refill. If you have any questions ...

The new guideline includes evidence-based recommendations for the use of subcutaneous immunoglobulin (SCIg) for maintenance treatment in CIDP. “The updated guideline should provide physicians ...

Aim: To report the interesting case of a patient with common variable immune deficiency disease who demonstrated varied responses to intravenous (IV) and subcutaneous (SC) immunoglobulin (Ig ...

Furthermore, Subcutaneous Immunoglobulin (SCIg) is gaining traction in homecare settings, particularly for the geriatric population and individuals with lifestyle-related illnesses. Meanwhile ...

(MENAFN- EIN Presswire) The global subcutaneous immunoglobulin market was valued at US$ 4.0 Bn in 2018 and is anticipated to expand at a CAGR of 13.1% from 2019 to 2027 Subcutaneous immunoglobulin ...

(Bloomberg) -- Australian biotech group CSL Ltd. has begun enrolling US patients in a late-stage study to test a ...

This approval introduces the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy in Japan, offering patients a new treatment option. HYQVIA combines subcutaneous immunoglobulin ...

Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and ...

The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma ...